Drug combination containing perindopril

A technology of perindopril and composition, applied in the field of chemical drugs, can solve problems such as poor drug stability

Inactive Publication Date: 2010-07-07
SHANGHAI PHARMA DONGYING JIANGSU PHARMA CO LTD
View PDF7 Cites 6 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0005] The purpose of the present invention is to provide a pharmaceutical composition con

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0021] Perindopril Arginine 2g

[0022] Microcrystalline Cellulose 50g

[0023] Lactose 25g

[0024] Starch 20g

[0025] 20% ethanol appropriate amount

[0026] Magnesium Stearate Appropriate amount

[0027]

[0028] Makes 1000 pieces

[0029] Take perindopril, grind it through a 80-100 mesh sieve, and mix it with starch, lactose and microcrystalline cellulose in sequence in an equal increment method. Add appropriate amount of 20% ethanol solution to make a suitable soft material, and granulate with a 20-mesh sieve. The wet granules are dried below 60°C, and the dry granules are sized with a 20-mesh sieve. Add magnesium stearate, mix well, fill in No. 3 hollow capsules, and get ready.

Embodiment 2

[0031] Get 4g of perindopril, 70g of microcrystalline cellulose, 55g of lactose, 20g of polycridine potassium, an appropriate amount of magnesium stearate and silicon dioxide, and press conventional techniques to make 1000 tablets.

[0032] The capsules obtained in Example 1 were placed in a thermostat with a relative humidity of 75% and a temperature of 60° C. for 6 months, and samples were taken and analyzed at 1, 2, 3, and 6 months, and compared with the 0-day sample.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses a drug combination containing perindopril. The drug combination comprises perindopril or salts thereof as the active components and contains one or more medicinal excipients. The drug combination of the invention can effectively improve the stability of perindopril, particularly, the content of the active components remains 98.86% after the accelerated test of capsules for 6 months.

Description

technical field [0001] The invention belongs to the field of chemical drugs, in particular to a pharmaceutical composition containing perindopril. Background technique [0002] Perindopril is chemically known as (2S, 3αS, 7αS)-((2-(1-(ethoxycarbonyl)-(S)-butylamino)-(S)-propionyl))octahydro-indole Indole-2-carboxylic acid. It is an angiotensin-converting enzyme inhibitor used in the treatment of cardiovascular diseases, especially in the treatment of hypertension and heart failure. Perindopril and pharmaceutical compositions containing it. [0003] Angiotensin-converting enzyme inhibitors are known to be degraded by: 1 side chain ester bond hydrolysis; 2 intramolecular cyclization; 3 chiral center isomerization; 4 oxidation. Perindopril is mainly degraded by hydrolysis and intramolecular cyclization. The degraded impurities have been referred to as impurities B and F in Ph. Eur. 5.0. Different methods of stabilizing pharmaceutical compositions of angiotensin converting ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/404A61P9/12A61P9/04
Inventor 黄乐群
Owner SHANGHAI PHARMA DONGYING JIANGSU PHARMA CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap